KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

West Pharmaceutical Services (WST) Shares Outstanding (Weighted Average) (2016 - 2025)

West Pharmaceutical Services' Shares Outstanding (Weighted Average) history spans 17 years, with the latest figure at $72.3 million for Q4 2025.

  • For Q4 2025, Shares Outstanding (Weighted Average) fell 0.96% year-over-year to $72.3 million; the TTM value through Dec 2025 reached $72.3 million, down 0.96%, while the annual FY2025 figure was $72.3 million, 0.96% down from the prior year.
  • Shares Outstanding (Weighted Average) for Q4 2025 was $72.3 million at West Pharmaceutical Services, roughly flat from $72.2 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $74.5 million in Q1 2023 and bottomed at $72.2 million in Q2 2025.
  • The 5-year median for Shares Outstanding (Weighted Average) is $74.0 million (2021), against an average of $73.7 million.
  • The largest annual shift saw Shares Outstanding (Weighted Average) increased 0.68% in 2021 before it fell 1.75% in 2024.
  • A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $74.4 million in 2021, then changed by 0.0% to $74.4 million in 2022, then fell by 0.13% to $74.3 million in 2023, then decreased by 1.75% to $73.0 million in 2024, then fell by 0.96% to $72.3 million in 2025.
  • Per Business Quant, the three most recent readings for WST's Shares Outstanding (Weighted Average) are $72.3 million (Q4 2025), $72.2 million (Q3 2025), and $72.2 million (Q2 2025).